$AKESO (09926.HK)$Announced, independent research and development of PD-1/CTLA-4 dual-antibody cardenolide single antibody injection solution "Kaitani" and VEGFR-2 monoclonal antibody "Puloxi", combined with chemotherapy for the treatment of advanced gastric adenocarcinoma or gastric/esophageal junction adenocarcinoma patients who have progressed with PD-1/L1 inhibitor combination chemotherapy. The registration phase III clinical study (AK109-301) of this combination therapy has recently completed the enrollment of the first patient.

Akeso stated that gastric cancer is one of the most common malignant tumors worldwide. The group's comprehensive clinical layout for first-line and second-line treatment of advanced gastric cancer is expected to further expand the indications for camdi in advanced gastric cancer and bring innovative and effective immune treatment solutions to patients with advanced gastric cancer.